The Economic Times

US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment

Hibsago, GSK's new hepatitis B treatment, recently secured approval from the US FDA, allowing patients to better manage their condition after therapy. This approval is vital as GSK aims for annual revenues of over 40 billion by 2031. The drug is already approved in Japan and is being assessed in China and Europe. Collaboration with Ionis Pharmaceuticals means they will receive milestone payments.